Rhea-AI Impact
Rhea-AI Sentiment
Rhea-AI Summary
OS Therapies (NYSE-A: OSTX) has partnered with B2i Digital to enhance investor outreach and raise awareness about its cancer immunotherapy research. The company’s lead candidate, OST-HER2, is an off-the-shelf immunotherapy targeting HER2-positive cancer cells, currently in Phase 2b trials for recurrent, resected metastatic osteosarcoma. The trial has completed enrollment and patient visits, with clinical data updates expected during the JP Morgan Healthcare Conference 2025.
Additionally, OS Therapies is developing a tunable Antibody-Drug Conjugate (ADC) platform aimed at providing tailored cancer treatments with improved efficacy and reduced side effects. B2i Digital will implement data-driven strategies to communicate the company’s progress and upcoming milestones to investors.
OS Therapies (NYSE-A: OSTX) ha stretto una partnership con B2i Digital per migliorare i rapporti con gli investitori e aumentare la consapevolezza sulla sua ricerca nell’immunoterapia contro il cancro. Il candidato principale dell’azienda, OST-HER2, è un’immunoterapia pronta all’uso che mira alle cellule tumorali positive per HER2, attualmente in sperimentazione di Fase 2b per l’osteosarcoma metastatico ricorrente e resezionato. La sperimentazione ha completato l’arruolamento e le visite ai pazienti, con aggiornamenti sui dati clinici previsti durante la JP Morgan Healthcare Conference 2025.
Inoltre, OS Therapies sta sviluppando una piattaforma di Antibody-Drug Conjugate (ADC) regolabile, mirata a fornire trattamenti personalizzati per il cancro con maggiore efficacia e minori effetti collaterali. B2i Digital implementerà strategie basate sui dati per comunicare i progressi dell’azienda e i prossimi traguardi agli investitori.
OS Therapies (NYSE-A: OSTX) se ha asociado con B2i Digital para mejorar la comunicación con los inversores y aumentar la conciencia sobre su investigación en inmunoterapia contra el cáncer. El candidato principal de la compañía, OST-HER2, es una inmunoterapia lista para usar que se dirige a las células cancerosas positivas para HER2, actualmente en ensayos de Fase 2b para el osteosarcoma metastásico recurrente y resecado. La prueba ha completado la inscripción y las visitas de pacientes, con actualizaciones de datos clínicos esperadas durante la JP Morgan Healthcare Conference 2025.
Además, OS Therapies está desarrollando una plataforma ajustable de Antibody-Drug Conjugate (ADC) destinada a proporcionar tratamientos personalizados para el cáncer con mayor eficacia y menos efectos secundarios. B2i Digital implementará estrategias basadas en datos para comunicar el progreso de la empresa y los próximos hitos a los inversores.
OS Therapies (NYSE-A: OSTX)는 투자자와의 소통을 강화하고 암 면역 요법 연구에 대한 인식을 높이기 위해 B2i Digital과 파트너십을 체결했습니다. 회사의 주요 후보인 OST-HER2는 HER2 양성 암세포를 표적으로 삼는 준비된 면역 요법으로, 현재 재발성 및 절제된 전이성 골육종에 대한 2b상 임상 시험 중입니다. 이번 시험은 등록 및 환자 방문을 완료했으며, JP Morgan Healthcare Conference 2025에서 임상 데이터 업데이트가 있을 예정입니다.
또한, OS Therapies는 개선된 효능과 부작용 감소를 통해 맞춤형 암 치료를 제공할 수 있는 조정 가능한 항체-약물 접합체(ADC) 플랫폼을 개발하고 있습니다. B2i Digital은 데이터 기반 전략을 통해 회사의 진행 상황과 다가오는 이정표를 투자자에게 전달할 것입니다.
OS Therapies (NYSE-A: OSTX) a noué un partenariat avec B2i Digital pour améliorer la communication avec les investisseurs et sensibiliser à ses recherches en immunothérapie contre le cancer. Le principal candidat de la société, OST-HER2, est une immunothérapie prête à l’emploi ciblant les cellules cancéreuses positives pour HER2, actuellement en essais de Phase 2b pour l’ostéosarcome métastatique récurrent et réséqué. L’essai a terminé son enrôlement et ses visites de patients, avec des mises à jour des données cliniques attendues lors de la JP Morgan Healthcare Conference 2025.
De plus, OS Therapies développe une plateforme ajustable d’anticorps-médicaments (ADC) visant à fournir des traitements personnalisés contre le cancer avec une efficacité améliorée et des effets secondaires réduits. B2i Digital mettra en œuvre des stratégies basées sur les données pour communiquer les progrès de l’entreprise et les prochaines étapes aux investisseurs.
OS Therapies (NYSE-A: OSTX) hat eine Partnerschaft mit B2i Digital geschlossen, um die Anlegerkommunikation zu verbessern und das Bewusstsein für die Krebs-Immuntherapieforschung zu schärfen. Der Hauptkandidat des Unternehmens, OST-HER2, ist eine gebrauchsfertige Immuntherapie, die auf HER2-positive Krebszellen abzielt und sich derzeit in Phase 2b-Studien für wiederkehrendes, reseziertes metastatisches Ostsarkom befindet. Die Studie hat die Rekrutierung und die Patientenbesuche abgeschlossen, mit klinischen Datenaktualisierungen, die während der JP Morgan Healthcare Conference 2025 erwartet werden.
Darüber hinaus entwickelt OS Therapies eine anpassbare Antikörper-Arzneimittel-Konjugat (ADC)-Plattform, die darauf abzielt, maßgeschneiderte Krebstherapien mit verbesserter Wirksamkeit und reduzierten Nebenwirkungen bereitzustellen. B2i Digital wird datengestützte Strategien umsetzen, um den Fortschritt des Unternehmens und anstehende Meilensteine den Investoren zu kommunizieren.
Positive
- Phase 2b trial for OST-HER2 has completed enrollment and all patient visits
- Clinical data update scheduled for JP Morgan Healthcare Conference 2025
- Development of tunable ADC platform for targeted cancer treatment
Insights
For retail investors, it’s important to understand that marketing partnerships like this, while important for corporate visibility, rarely impact stock performance significantly. The key value drivers remain the clinical trial results, regulatory milestones and pipeline advancement – none of which are materially affected by this announcement.
- Digital Marketing Campaign to Highlight Clinical-Stage Cancer Innovation OST-HER2 that activates cellular immunity against HER2+ cancer
- OS Therapies Joins the B2i Digital Featured Companies Program
NEW YORK–(BUSINESS WIRE)– OS Therapies, Inc. (NYSE-A: OSTX), a clinical-stage biotechnology company advancing immunotherapies and targeted drug conjugates for cancer treatment, has partnered with B2i Digital to enhance investor outreach. B2i Digital will implement data-driven strategies to raise awareness about OS Therapies’ pioneering research and upcoming milestones, including its potentially pivotal Phase 2b clinical trial for OST-HER2 in the rare pediatric orphan disease recurrent, resected metastatic osteosarcoma.
“OS Therapies is an exceptional addition to our platform,” said David Shapiro, CEO of B2i Digital. “Their innovative cancer treatments, such as OST-HER2 for recurrent, resected metastatic osteosarcoma, hold significant potential to address unmet medical needs in oncology. We look forward to helping them share their progress and vision with the investment community.”
B2i Digital will highlight OS Therapies’ lead candidate, OST-HER2, an off-the-shelf immunotherapy designed to activate the immune system to target HER2-positive cancer cells. The Phase 2b trial for OST-HER2 in recurrent, resected metastatic osteosarcoma has completed enrollment and all patient visits, with the next clinical data update expected to be announced during the week of the JP Morgan Healthcare Conference 2025. Additionally, OS Therapies is advancing its tunable Antibody-Drug Conjugate (ADC) platform, which offers tailored cancer treatments with the potential improved efficacy, and reduced side effects.
“Our collaboration with B2i Digital aligns with our mission to bring life-changing treatments to patients and increase awareness of the unique therapeutic potential of our pipeline,” said Paul Romness, MHP, CEO of OS Therapies. “We are eager to engage with investors as we prepare for key milestones that could reshape how challenging cancers, especially metastatic disease, are addressed.”
About B2i Digital, Inc.
B2i Digital, Inc. leverages the latest digital marketing technologies and investor conferences to share a company’s story with retail investors, institutional investors, and research analysts. B2i Digital creates robust profiles for companies on its platform, b2idigital.com, and launches targeted digital marketing campaigns to support their online and offline investor engagement efforts. B2i Digital was founded in 2021 by David Shapiro, previously the Chief Marketing Officer and an investment banker at Maxim Group, LLC. David was also one of the founders of Maxim’s investor awareness platform, M-Vest.com.
About OS Therapies
OS Therapies is a clinical stage oncology company focused on the identification, development, and commercialization of treatments for Osteosarcoma (OS) and other solid tumors. OST-HER2, the Company’s lead asset, is an immunotherapy leveraging the immune-stimulatory effects of Listeria bacteria to initiate a strong immune response targeting the HER2 protein. The Company has completed enrollment for a 41-patient Phase 2b clinical trial of OST-HER2 in resected, recurrent osteosarcoma, with results expected in the fourth quarter of 2024. OST-HER2 has completed a Phase 1 clinical study primarily in breast cancer patients, in addition to showing preclinical efficacy data in various models of breast cancer. OST-HER2 has been conditionally approved by the U.S. Department of Agriculture for the treatment of canines with osteosarcoma. In addition, OS Therapies is advancing its next-generation Antibody Drug Conjugate (ADC) platform, known as tunable ADC (tADC), which features tunable, tailored antibody-linker-payload candidates. This platform leverages the Company’s proprietary silicone linker technology, enabling the delivery of multiple payloads per linker. For more information, please visit www.ostherapies.com.
Forward-Looking Statements
Statements in this press release about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute forward-looking statements within the meaning of the federal securities laws. These forward-looking statements and terms such as “anticipate,” “expect,” “intend,” “may,” “will,” “should” or other comparable terms involve risks and uncertainties because they relate to events and depend on circumstances that will occur in the future. Those statements include statements regarding the intent, belief or current expectations of OS Therapies and members of its management, as well as the assumptions on which such statements are based. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, including those described under the section entitled “Risk Factors” of our Registration Statement on Form S-1 declared effective by the Securities and Exchange Commission (the “SEC”) on July 31, 2024, as well as any of our periodic reports filed with the SEC, and that actual results may differ materially from those indicated by such forward-looking statements. Any forward-looking statements contained in this press release speak only as of the date hereof, and, except as required by the federal securities laws, OS Therapies specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241226520958/en/
B2i Digital Contact Information:
David Shapiro
Chief Executive Officer
B2i Digital, Inc.
212.579.4844 Office
https://www.instagram.com/b2i_digital
https://www.facebook.com/b2idigital
https://www.linkedin.com/company/b2i-digital
OS Therapies Contact Information:
Jack Doll
410-297-7793
https://www.instagram.com/ostherapies/
https://www.facebook.com/OSTherapies/
https://www.linkedin.com/company/os-therapies/
Source: OS Therapies, Inc.
FAQ
When will OSTX release clinical data for its Phase 2b OST-HER2 trial?
OS Therapies plans to announce clinical data updates for the OST-HER2 Phase 2b trial during the JP Morgan Healthcare Conference 2025.
What is the current status of OSTX’s Phase 2b trial for metastatic osteosarcoma?
The Phase 2b trial for OST-HER2 in recurrent, resected metastatic osteosarcoma has completed both enrollment and all patient visits.
What cancer treatments is OSTX currently developing?
OSTX is developing OST-HER2, an off-the-shelf immunotherapy for HER2-positive cancers, and a tunable Antibody-Drug Conjugate (ADC) platform for targeted cancer treatments.
What is the purpose of OSTX’s partnership with B2i Digital?
The partnership aims to enhance investor outreach and raise awareness about OS Therapies’ cancer research and upcoming milestones through data-driven marketing strategies.
